Profile data is unavailable for this security.
About the company
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The Company is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. The Company’s ARCALYST is interleukin-1alpha (IL-1α), and interleukin-1beta (IL-1β), cytokine trap for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children. Its KPL-404 is an investigational monoclonal antibody inhibitor of CD40-CD154 interaction. The Company’s Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRα).
- Revenue in USD (TTM)338.93m
- Net income in USD-10.23m
- Incorporated2015
- Employees297.00
- LocationKiniksa Pharmaceuticals LtdClarendon House, 2 Church StreetHAMILTON HM11BermudaBMU
- Phone+1 4417 814399100
- Websitehttps://www.kiniksa.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BioCryst Pharmaceuticals Inc | 355.40m | -208.59m | 1.62bn | 536.00 | -- | -- | -- | 4.56 | -1.07 | -1.07 | 1.81 | -2.31 | 0.727 | 0.1787 | 6.51 | 663,050.40 | -42.67 | -47.95 | -54.00 | -64.89 | 98.56 | 97.06 | -58.69 | -114.94 | 3.48 | -1.00 | 2.30 | -- | 22.37 | 74.21 | 8.33 | -- | 42.73 | -- |
| Soleno Therapeutics Inc | 0.00 | -52.03m | 1.68bn | 33.00 | -- | 11.27 | -- | -- | -2.68 | -2.68 | 0.00 | 4.30 | 0.00 | -- | -- | 0.00 | -55.24 | -53.90 | -62.26 | -61.85 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -62.00 | -- | -- | -- |
| Edgewise Therapeutics Inc | 0.00 | -105.85m | 1.77bn | 92.00 | -- | 3.31 | -- | -- | -1.53 | -1.53 | 0.00 | 5.73 | 0.00 | -- | -- | 0.00 | -23.52 | -- | -24.25 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.08 | -- | -- | -- |
| Veracyte Inc | 375.47m | -68.18m | 1.81bn | 815.00 | -- | 1.62 | -- | 4.83 | -0.9346 | -0.9346 | 5.12 | 14.64 | 0.3186 | 7.47 | 8.15 | 460,703.10 | -5.78 | -6.33 | -6.08 | -6.69 | 68.54 | 67.10 | -18.16 | -20.99 | 4.69 | -- | 0.00009 | -- | 21.76 | 31.45 | -103.51 | -- | 39.67 | -- |
| Kiniksa Pharmaceuticals Ltd | 338.93m | -10.23m | 1.86bn | 297.00 | -- | -- | -- | 5.49 | -0.1788 | -0.1788 | 4.68 | -- | -- | -- | -- | 1,141,179.00 | -- | -16.49 | -- | -18.72 | 87.73 | -- | -3.02 | -53.64 | -- | -- | -- | -- | 22.74 | -- | -92.32 | -- | -52.35 | -- |
| Keros Therapeutics Inc | 234.00k | -160.30m | 1.89bn | 141.00 | -- | 4.16 | -- | 8,067.99 | -5.14 | -5.14 | 0.0075 | 12.59 | 0.0005 | -- | -- | 1,720.59 | -36.84 | -35.95 | -38.35 | -38.07 | -- | -- | -68,505.13 | -1,237.26 | -- | -- | 0.00 | -- | -- | -56.77 | -46.15 | -- | 62.57 | -- |
| Akero Therapeutics Inc | 0.00 | -179.27m | 1.94bn | 58.00 | -- | 2.30 | -- | -- | -3.20 | -3.20 | 0.00 | 12.24 | 0.00 | -- | -- | 0.00 | -28.43 | -37.73 | -29.53 | -40.13 | -- | -- | -- | -- | -- | -- | 0.0395 | -- | -- | -- | -35.46 | -- | -- | -- |
| Vera Therapeutics Inc | 0.00 | -94.30m | 2.01bn | 55.00 | -- | 5.65 | -- | -- | -2.04 | -2.04 | 0.00 | 6.49 | 0.00 | -- | -- | 0.00 | -29.99 | -- | -31.92 | -- | -- | -- | -- | -- | -- | -- | 0.124 | -- | -- | -- | -7.79 | -- | -- | -- |
| Arvinas Inc | 71.30m | -354.80m | 2.03bn | 445.00 | -- | 3.32 | -- | 28.46 | -6.05 | -6.05 | 1.22 | 8.93 | 0.0597 | -- | 12.08 | 160,224.70 | -29.59 | -22.01 | -37.90 | -26.47 | -- | -- | -495.65 | -316.55 | -- | -- | 0.0012 | -- | -40.26 | 40.53 | -30.02 | -- | 0.4852 | -- |
| Mirum Pharmaceuticals Inc | 224.00m | -158.56m | 2.04bn | 278.00 | -- | 8.69 | -- | 9.12 | -3.82 | -3.82 | 5.19 | 4.99 | 0.4546 | 4.24 | 5.62 | 848,477.30 | -32.18 | -38.93 | -38.17 | -44.88 | 73.26 | -- | -70.79 | -190.71 | 3.47 | -- | 0.5667 | -- | 141.85 | -- | -20.45 | -- | 21.81 | -- |
| Neumora Therapeutics Inc | 0.00 | -254.02m | 2.06bn | 120.00 | -- | 4.84 | -- | -- | -1.55 | -1.55 | 0.00 | 2.66 | 0.00 | -- | -- | 0.00 | -60.32 | -- | -63.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.23 | -- | -- | -- |
| Syndax Pharmaceuticals Inc | 0.00 | -240.63m | 2.08bn | 112.00 | -- | 4.23 | -- | -- | -3.22 | -3.22 | 0.00 | 5.79 | 0.00 | -- | -- | 0.00 | -47.99 | -27.90 | -51.84 | -30.15 | -- | -- | -- | -324.34 | -- | -- | 0.00004 | -- | -- | -- | -40.19 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Fairmount Funds Management LLCas of 31 Mar 2024 | 3.20m | 7.92% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 3.09m | 7.65% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 2.93m | 7.25% |
| Baker Bros. Advisors LPas of 05 Jun 2024 | 2.86m | 7.08% |
| Rubric Capital Management LPas of 31 Mar 2024 | 2.20m | 5.43% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 1.89m | 4.67% |
| Pictet Asset Management SAas of 31 Mar 2024 | 1.46m | 3.61% |
| Braidwell LPas of 31 Mar 2024 | 1.39m | 3.44% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 958.81k | 2.37% |
| Geode Capital Management LLCas of 31 Mar 2024 | 725.51k | 1.79% |
